StockNews.AI
MRNA
Benzinga
40 days

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

1. FDA approved MRNA's Spikevax for children at increased COVID-19 risk. 2. Updated Spikevax expected by 2025-2026 for eligible U.S. populations. 3. Moderna asserts patent rights against Pfizer and BioNTech's vaccine. 4. FDA limits COVID vaccine approvals to high-risk groups only. 5. MRNA stock rose 3.60% following the FDA approval news.

5m saved
Insight
Article

FAQ

Why Bullish?

The FDA's approval expands MRNA's market reach, enhancing revenue potential. Historical approvals have often led to stock price increases.

How important is it?

The FDA approval is a significant milestone that impacts MRNA's future earnings and market position.

Why Long Term?

The continuous demand for COVID vaccines, especially for children, supports long-term growth projections and market share gains.

Related Companies

Related News